v3.25.0.1
Collaborations (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's receivable from Janssen $ 10,919 $ 11,155  
AbbVie's payable to Janssen $ 31,945 30,650  
Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Janssen Biotech, Inc | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 162 228 $ 268
AbbVie's receivable from Janssen 237 236  
AbbVie's payable to Janssen 282 307  
Janssen Biotech, Inc | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 1,140 1,245 1,607
Janssen Biotech, Inc | Collaborative arrangement | International      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
International - AbbVie's share of profits (included in net revenues) 899 931 1,142
Genentech, Inc. | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 990 869 778
AbbVie's share of development costs (included in R&D) 84 109 121
Genentech, Inc. | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 29 $ 41 $ 37